小剂量右美托咪定对宫颈癌微创术后胃肠道反应的影响

摘要： 目的 探讨小剂量右美托咪定对宫颈癌微创术后胃肠道反应的影响。方法 选取2014 年2 月－ 2016 年9 月在该院接受宫颈癌微创术的患者94 例，依据随机数表法分为观察组（小剂量右美托咪定）和对 照组（生理盐水），比较两组患者的恶心、呕吐发生率及胃动素水平。结果 观察组47 例，Ⅱ级恶心7 例，Ⅲ 级恶心2 例，总发生率为19.15% ；对照组47 例，Ⅱ级恶心11 例，Ⅲ级恶心4 例，Ⅳ级恶心2 例，总发生率为 36.17%，差异具有统计学意义（P <0.05）。观察组47 例，Ⅱ级呕吐6 例，Ⅲ级呕吐1 例，总发生率为14.89% ； 对照组47 例，Ⅱ级呕吐4 例，Ⅲ级呕吐5 例，Ⅳ级呕吐1 例，总发生率为21.28%，差异具有统计学意义（P <0.05）。 术前1 h 两组患者的胃动素差异无统计学意义（P >0.05）。术后6、12 和24 h，观察组患者的胃动素水平明显 低于对照组，差异具有统计学意义（P <0.05）。结论 小剂量右美托咪定能够有效预防和缓解宫颈癌微创术 后胃肠道反应，避免胃动素过度释放，值得临床推广。
Abstract: Objective To investigate the effect of low dose Dexmedetomidine on gastrointestinal reaction after minimally invasive surgery for cervical cancer. Methods 94 patients with cervical cancer treated with minimally invasive surgery from February 2014 to September 2016 were selected. According to the random number table method, the patients were divided into observation group (low-dose Dexmedetomidine) and control group (saline). The incidence of nausea and vomiting, the motilin level were compared between the two groups. Results The observation group was 47 cases, grade Ⅱ nausea in 7 cases, grade Ⅲ nausea in 2 cases, the total incidence was 19.15%; 47 cases in the control group, 11 cases of grade Ⅱ nausea, grade Ⅳ nausea in 4 cases, grade 2 nausea in 2 cases, the rate was 36.17%, the difference was statistically significant (P < 0.05). 47 cases of grade Ⅱ vomiting in 4 cases, grade Ⅲ vomiting in 5 cases, grade Ⅳ vomiting in 1 case, the total incidence rate was 14.89%, grade Ⅱ in 4 case, grade Ⅲ vomiting in 5 cases, grade Ⅳ vomiting in 1 case, the total incidence was 21.28%, the difference was statistically significant (P < 0.05). There was no significant difference in motilin level between the two groups (P > 0.05). At 6 h, 12 h and 24 h after operation, the levels of motilin in the observation group were significantly lower than those in the control group, the difference was statistically significant (P < 0.05). Conclusion Low dose Dexmedetomidine can effectively prevent and alleviate the gastrointestinal reaction after minimally invasive surgery for cervical cancer, and avoid the excessive release of motilin, worthy of clinical promoting.